Subamnex Ameliorates Hypoxia-Induced Pulmonary Arterial Hypertension through Modulation of the STAT3/p-STAT3 Pathway - PubMed
21 hours ago
- #STAT3 pathway
- #PAH treatment
- #vascular remodeling
- Subamnex, a naphthalimide-polyamine derivative, was designed and synthesized to treat hypoxia-induced pulmonary arterial hypertension (PAH).
- It inhibits proliferation and migration of pulmonary arterial smooth muscle cells (PASMCs) by targeting IL-6-induced STAT3 phosphorylation.
- The compound regulates downstream effectors like NEAT1, Pim-1, and the Bax/Bcl-2 balance to attenuate vascular remodeling.
- Subamnex offers a novel strategy to reverse PAH vascular remodeling, moving beyond symptom alleviation.